Worth reading
55In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
1.4
% (year-on-year change in revenue)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)1 September 2025–28 February 2026ConsolidatedJapanese GAAPNet Sales16,846Millions of yenYear on year +1.4%Progress 49.3%
Operating profit1,251Millions of yenYear on year -3.4%Progress 49.2%
Ordinary income1,194Millions of yenYear on year -10.4%Progress 48.8%
Net income attributable to owners of the parent801Millions of yenYear on year -9.1%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥55.76
Financial position at period-end
Total assets50,254Millions of yen
of which net assets 16,224 Millions of yenEquity ratio 31.9%vs. prior year-end +1.0pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+1,828,842
Investment-2,173,542
Financials-47,544
Net change-392,244
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥10,824,499 thousand
Segment revenueHealthcare Business ¥9,825,170 thousand (YoY +2.5%), Pharmaceuticals Business ¥1,283,394 thousand (YoY +3.1%), Department Store Business ¥2,360,189 thousand (YoY +0.4%), Foodservice Business ¥1,228,443 thousand (YoY +8.6%), Real Estate and Construction Contracting Business ¥1,112,111 thousand (YoY -18.1%), Other Businesses ¥1,036,869 thousand
Segment profitHealthcare Business ¥1,163,095 thousand (YoY -15.8%), Pharmaceuticals Business ¥158,275 thousand (YoY +73.4%), Department Store Business ¥30,742 thousand (YoY -11.2%), Foodservice Business ¥-18,615 thousand, Real Estate and Construction Contracting Business ¥14,023 thousand, Other Businesses ¥-79,820 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales34,137 Millions of yen (YoY +4.5%)
Operating profit2,545 Millions of yen (YoY +5.6%)
Ordinary income2,445 Millions of yen (YoY +0.1%)
Profit attributable to owners of the parent1,545 Millions of yen (YoY +6.7%)
Revision to Earnings ForecastNet Sales Not disclosed → 34,137 Millions of yen / Operating profit Not disclosed → 2,545 Millions of yen / Ordinary income Not disclosed → 2,445 Millions of yen / Profit attributable to owners of the parent Not disclosed → 1,545 Millions of yen
Annual Dividend Forecast¥34 → ¥36
Factors Behind Changes in Business Performance
Revenue was ¥16,846 million, reflecting higher revenue and profit in the Pharmaceuticals Business, which maintained strong performance, as well as higher revenue in the Healthcare Business and other factors. In the Pharmaceuticals Business, increased OEM orders for over-the-counter drugs and prescription generic drugs drove revenue. In the Healthcare Business, an increase in inbound customers, promotional events for premium customers and advertising for foods with function claims contributed to revenue.
Disclosure regarding the going concern assumption
Not applicable (no matters to report in the notes on the going concern assumption)
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 / Excluded 0 / Company name No applicable matters
Material subsequent eventsOf the first series of stock acquisition rights issued by the subsidiary さいか屋, 1,040 rights were exercised between 9 March and 31 March 2026, and 104,000 common shares were issued. Capital stock and capital surplus each increased by ¥16.749 million.
Impairment lossNo applicable matters
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥5,401 thousand, Insurance proceeds received ¥23,623 thousand / Extraordinary loss Loss on sale of fixed assets ¥1,360 thousand, Loss on Disposal of Fixed Assets ¥3,991 thousand
Depreciation and amortization¥564,128 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingWhether applicable Yes / Subject person For analysts
Issued Shares at Period-End14,559,699
Treasury Shares at Period-End94
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 September 2025–28 February 2026 |
| Net Sales | 16,846 Millions of yen (YoY +1.4%) |
| Operating profit | 1,251 Millions of yen (YoY -3.4%) |
| Ordinary income | 1,194 Millions of yen (YoY -10.4%) |
| Profit attributable to owners of the parent | 801 Millions of yen (YoY -9.1%) |
| Net income per share | ¥55.76 |
| Equity ratio | End of the current fiscal period 31.9 / End of previous period 30.9 |
| Total assets | 50,254 Millions of yen |
| Net assets | 16,224 Millions of yen |
| Cash flows from operating activities | ¥1,828,842 thousand |
| Cash flows from investing activities | ¥-2,173,542 thousand |
| Cash flows from financing activities | ¥-47,544 thousand |
| Cash and cash equivalents at end of period | ¥10,824,499 thousand |
| Full-year earnings forecast | Net Sales 34,137 Millions of yen (YoY +4.5%) / Operating profit 2,545 Millions of yen (YoY +5.6%) / Ordinary income 2,445 Millions of yen (YoY +0.1%) / Profit attributable to owners of the parent 1,545 Millions of yen (YoY +6.7%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → 34,137 Millions of yen / Operating profit Not disclosed → 2,545 Millions of yen / Ordinary income Not disclosed → 2,445 Millions of yen / Profit attributable to owners of the parent Not disclosed → 1,545 Millions of yen |
| Annual Dividend Forecast | ¥34 → ¥36 |
| Segment revenue | Healthcare Business ¥9,825,170 thousand (YoY +2.5%), Pharmaceuticals Business ¥1,283,394 thousand (YoY +3.1%), Department Store Business ¥2,360,189 thousand (YoY +0.4%), Foodservice Business ¥1,228,443 thousand (YoY +8.6%), Real Estate and Construction Contracting Business ¥1,112,111 thousand (YoY -18.1%), Other Businesses ¥1,036,869 thousand |
| Segment profit | Healthcare Business ¥1,163,095 thousand (YoY -15.8%), Pharmaceuticals Business ¥158,275 thousand (YoY +73.4%), Department Store Business ¥30,742 thousand (YoY -11.2%), Foodservice Business ¥-18,615 thousand, Real Estate and Construction Contracting Business ¥14,023 thousand, Other Businesses ¥-79,820 thousand |
| Depreciation and amortization | ¥564,128 thousand |
| Impairment loss | No applicable matters |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥5,401 thousand, Insurance proceeds received ¥23,623 thousand / Extraordinary loss Loss on sale of fixed assets ¥1,360 thousand, Loss on Disposal of Fixed Assets ¥3,991 thousand |
| Disclosure regarding the going concern assumption | Not applicable (no matters to report in the notes on the going concern assumption) |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name No applicable matters |
| Material subsequent events | Of the first series of stock acquisition rights issued by the subsidiary さいか屋, 1,040 rights were exercised between 9 March and 31 March 2026, and 104,000 common shares were issued. Capital stock and capital surplus each increased by ¥16.749 million. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person For analysts |
| Issued Shares at Period-End | 14,559,699 |
| Treasury Shares at Period-End | 94 |
| Factors Behind Changes in Business Performance | Revenue was ¥16,846 million, reflecting higher revenue and profit in the Pharmaceuticals Business, which maintained strong performance, as well as higher revenue in the Healthcare Business and other factors. In the Pharmaceuticals Business, increased OEM orders for over-the-counter drugs and prescription generic drugs drove revenue. In the Healthcare Business, an increase in inbound customers, promotional events for premium customers and advertising for foods with function claims contributed to revenue. |
Items this document does not state (5)
Operating MarginPayout ratioShareholder Return PolicyRegional salesOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In addition to higher revenue and profit in the Pharmaceuticals Business, which maintained strong performance, revenue increased due to higher revenue in the Healthcare Business and other factors. For the second half, the company expects the Pharmaceuticals Business to remain strong and anticipates higher orders in the Real Estate and Construction Contracting Business, driven by rising demand for existing homes.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.